Literature DB >> 18055516

AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure.

Jasmina Varagic1, Edward D Frohlich, Dinko Susic, Jwari Ahn, Luis Matavelli, Begoña López, Javier Díez.   

Abstract

Our recent studies have demonstrated that salt excess in the spontaneously hypertensive rat (SHR) produces a modestly increased arterial pressure while promoting marked myocardial fibrosis and structural damage associated with altered coronary hemodynamics and ventricular function. The present study was designed to determine the efficacy of an angiotensin II type 1 (AT(1)) receptor blocker (ARB) in the prevention of pressure increase and development of target organ damage from high dietary salt intake. Eight-week-old SHRs were given an 8% salt diet for 8 wk; their age- and gender-matched controls received standard chow. Some of the salt-loaded rats were treated concomitantly with ARB (candesartan; 10 mg kg(-1) day(-1)). The ARB failed to reduce the salt-induced rise in pressure, whereas it significantly attenuated left ventricular (LV) remodeling (mass and wall thicknesses), myocardial fibrosis (hydroxyproline concentration and collagen volume fraction), and the development of LV diastolic dysfunction, as shown by longer isovolumic relaxation time, decreased ratio of peak velocity of early to late diastolic waves, and slower LV relaxation (minimum first derivative of pressure over time/maximal LV pressure). Without affecting the increased pulse pressure by high salt intake, the ARB prevented the salt-induced deterioration of coronary and renal hemodynamics but not the arterial stiffening or hypertrophy (pulse wave velocity and aortic mass index). Additionally, candesartan prevented the salt-induced increase in kidney mass index and proteinuria. In conclusion, the ARB given concomitantly with dietary salt excess ameliorated salt-related structural and functional cardiac and renal abnormalities in SHRs without reducing arterial pressure. These data clearly demonstrated that angiotensin II (via AT(1) receptors), at least in part, participated importantly in the pressure-independent effects of salt excess on target organ damage of hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055516     DOI: 10.1152/ajpheart.00737.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  33 in total

Review 1.  High salt intake as a multifaceted cardiovascular disease: new support from cellular and molecular evidence.

Authors:  Marcelo Perim Baldo; Sérgio Lamêgo Rodrigues; José Geraldo Mill
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

2.  Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Javad Habibi; Roger D Tilmon; James R Sowers; Carlos M Ferrario
Journal:  Am J Nephrol       Date:  2010-11-02       Impact factor: 3.754

Review 3.  Genetic architecture of complex traits predisposing to nephropathy: hypertension.

Authors:  Steven C Hunt
Journal:  Semin Nephrol       Date:  2010-03       Impact factor: 5.299

4.  Salt-induced renal injury in SHRs is mediated by AT1 receptor activation.

Authors:  Dinko Susic; Edward D Frohlich; Hiroyuki Kobori; Weijian Shao; Dale Seth; L Gabriel Navar
Journal:  J Hypertens       Date:  2011-04       Impact factor: 4.844

Review 5.  Toll-like Receptors in the Vascular System: Sensing the Dangers Within.

Authors:  Styliani Goulopoulou; Cameron G McCarthy; R Clinton Webb
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

6.  Salt, arterial pressure, and cardiovascular and renal damage.

Authors:  Dinko Susic; Hassan Fares; Edward D Frohlich
Journal:  Ochsner J       Date:  2009

7.  An updated concept for left ventricular hypertrophy risk in hypertension.

Authors:  Edward D Frohlich
Journal:  Ochsner J       Date:  2009

8.  Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.

Authors:  Yoshihiro Kiya; Shin-Ichiro Miura; Masahiro Fujino; Satoshi Imaizumi; Sadashiva S Karnik; Keijiro Saku
Journal:  Clin Exp Hypertens       Date:  2010-01       Impact factor: 1.749

9.  Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein.

Authors:  Marcela Herrera; Matthew A Sparks; Adolfo R Alfonso-Pecchio; Lisa M Harrison-Bernard; Thomas M Coffman
Journal:  Hypertension       Date:  2012-11-12       Impact factor: 10.190

10.  Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Leanne Groban; Mark C Chappell; E Ann Tallant; Patricia E Gallagher; Carlos M Ferrario
Journal:  Ther Adv Cardiovasc Dis       Date:  2009-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.